Lixte (LIXT) Stock Jumps On Positive Feedback For Lead Drug Candidate

The current trading session has seen a notable upswing of 52.29% in the shares of Lixte Biotechnology Holdings, Inc. (NASDAQ: LIXT), currently valued at $3.43. This surge in LIXT stock is ascribed to the acclaim received by the company’s lead drug candidate.

Lixte Biotechnology (LIXT) has disclosed the publication of preclinical data in the digital pages of Cancer Discovery. The disseminated findings underscore the capability of LIXT’s leading clinical compound, LB-100, to coerce cancerous cells into relinquishing their carcinogenic properties, as delineated in the paper titled “Paradoxical activation of oncogenic signaling as a cancer treatment strategy.”

Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.

Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!

Get the FREE Report with all the details here.


This revelation introduces a potential novel treatment avenue, supplementing LIXTE’s ongoing trio of clinical trials. As elucidated in the forthcoming July 2024 issue and concurrently released online, LB-100 has exhibited the capacity to induce a hyper-activation of signaling mechanisms responsible for the aberrant proliferation of cancer cells—a departure from conventional cancer therapies.

The orchestrated hyper-stimulation of cancer signals, when combined with a WEE1 kinase inhibitor, has demonstrated remarkable efficacy in eradicating colon cancer cells both in animal models and in vitro cultures. Notably, therapy resistance constitutes a primary cause of mortality in cancer cases.

Remarkably, resistance to LB-100 treatment appears to correlate with a reduction in the malignancy of cancer cells. Specifically observed in colon cancer cells, resistance to LB-100 led to a loss of key cancerous features, rendering the cells incapable of tumor formation in experimental animal models—a phenomenon termed “tumor suppressive drug resistance,” unique to LB-100.

The team of scientists behind these groundbreaking discoveries, led by Professor René Bernards at the Netherlands Cancer Institute and Oncode Institute in Amsterdam, comprises luminaries in the realm of molecular carcinogenesis. Professor Bernards, who also serves on the Board of Directors of LIXTE, spearheads this endeavor.

The distinctive impact of LB-100 on cancer cells lies in its coercion of cancer cells towards less malignancy as the sole recourse for survival—a concept that will be subject to clinical evaluation, distinct from the ongoing exploration of LB-100’s synergistic potential with checkpoint immunotherapy and chemotherapy in the three existing clinical trials.

Most Popular